Clearside Biomedical (CLSD) Projected to Post Earnings on Tuesday

Clearside Biomedical (NASDAQ:CLSD) is expected to release its earnings data after the market closes on Tuesday, March 11th. Analysts expect Clearside Biomedical to post earnings of ($0.13) per share and revenue of $0.29 million for the quarter.

Clearside Biomedical Trading Down 4.9 %

Shares of NASDAQ CLSD opened at $0.93 on Friday. The stock has a market cap of $70.37 million, a price-to-earnings ratio of -2.06 and a beta of 2.10. Clearside Biomedical has a 52 week low of $0.77 and a 52 week high of $2.12. The company’s 50-day moving average price is $0.96 and its 200 day moving average price is $1.06.

Analyst Ratings Changes

A number of research analysts have issued reports on CLSD shares. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Thursday. StockNews.com upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Thursday. Finally, Chardan Capital restated a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Friday, November 15th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.